<DOC>
<DOCNO>EP-0653439</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Stabilized oligonucleotids and the use thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P3100	C12N1509	C07H2104	A61K3170	C12N1509	A61P3500	C07H2100	A61K3170	A61K317088	C07H2100	A61K317088	A61P3112	A61P3122	A61P3500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C12N	C07H	A61K	C12N	A61P	C07H	A61K	A61K	C07H	A61K	A61P	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P31	C12N15	C07H21	A61K31	C12N15	A61P35	C07H21	A61K31	A61K31	C07H21	A61K31	A61P31	A61P31	A61P35	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to stabilised oligonucleotides in which at least one non-terminal pyrimidine nucleoside is modified, and to the use thereof as diagnostic aid or pharmaceutical for the treatment of viral infections, cancer or disorders in which integrins or cell-cell adhesion receptors are active.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
AVENTIS PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
AVENTIS PHARMA DEUTSCHLAND GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HELSBERG MATTHIAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KRETZSCHMAR GERHARD DR
</INVENTOR-NAME>
<INVENTOR-NAME>
MAG MATTHIAS
</INVENTOR-NAME>
<INVENTOR-NAME>
PEYMAN ANUSCHIRWAN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
UHLMANN EUGEN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WINKLER IRVIN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
HELSBERG, MATTHIAS, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KRETZSCHMAR, GERHARD, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
MAG, MATTHIAS
</INVENTOR-NAME>
<INVENTOR-NAME>
PEYMAN, ANUSCHIRWAN, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
UHLMANN, EUGEN, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
WINKLER, IRVIN, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
An oligonucleotide of the formula 

 
wherein at least one non-terminal pyrimidine nucleoside is modified 

and the 5' and/or 3' ends of the oligonucleotide are additionally 
modified. 
An oligonucleotide as claimed in claim 1, wherein 2-10 non-terminal 
pyrimidine nucleosides are modified.  

 
An oligonucleotide as claimed in claim 1 or 2, wherein 3-6 non-terminal 
pyrimidine nucleosides are modified. 
An oligonucleotide as claimed in any of claims 1-3, wherein one or 
more groups of at least 1-4 nucleotides which are linked to each other 

are not modified. 
An oligonucleotide as claimed in any of claims 1-4, wherein the 
modification is defined as 


(a) replacement of at least one 3' and/or 5' phosphodiester bond of 
adjacent nucleotides and/or 
(b) dephospho bonding of adjacent nucleotides and/or 
(c) replacement of at least one sugar radical and/or 
(d) replacement of at least one naturally occurring nucleoside. 
An oligonucleotide as claimed in claim 5, wherein the modification is 
defined as 


(a) a phosphorothioate, phosphorodithioate, NR
1
R
2
-phosphoramidate, 
boranophosphate, phosphate-(C
1
-C
21
)-O-alkyl ester, 
phosphate-[(C
6
-C
12
)aryl-(C
1
-C
21
)-O-alkyl] ester, 

2,2,2-trichlorodimethylethyl phosphonate, (C
1
-C
8
)-alkyl phosphonate, 
(C
6
-C
12
)-aryl phosphonate bond of adjacent 
nucleotides, in which 


R
1
 and R
2
independently of one another are hydrogen or C
1
-C
18
-alkyl, 
C
6
-C
20
-aryl, (C
6
-C
14
)-aryl-(C
1
-C
8
)-alkyl or -(CH
2
)
c
-[NH(CH
2
)
c
]
d
-NR
3
R
3
, 
in which c is an integer from 2 to 6 and d is an integer 

from 0 to 6, and R
3
 radicals independently of one another are 
hydrogen, C
1
-C
6
-alkyl or C
1
-C
4
-alkoxy-C
1
-C
6
-alkyl, or 
R
1
 and R
2
together with the nitrogen atom to which they are attached 
form a 5-6-membered heterocyclic ring which can optionally 

additionally contain a further heteroatom from the series 
consisting of O, S and N, 
(b) a formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, 
methylenedimethylhydrazo, dimethylene sulfone or silyl bond of 

adjacent nucleotides, 
(c) a replacement of the sugar-phosphate backbone by 
morpholinonucleoside oligomers or 
(d) a replacement of the β-D-2'-deoxyribose by β-D-2'-deoxyribose, 
L-2'-deoxyribose, 2'-F-2'-deoxyribose,  

 
2'-O-(C
1
-C
6
)alkyl-ribose, 2'-O-(C
2
-C
6
)alkenyl-ribose, 
2'-NH
2
-2'-deoxyribose, β-D-xylofuranose, α-arabinofuranose, 
2,4-dideoxy-β-D-erythro-hexo-pyranose, carbocyclic or open-chain 

sugar analogs or bicyclo sugar analogs, or 
(e) a replacement of the natural nucleoside bases by 
5-(hydroxymethyl)uridine, 5-aminouridine, pseudouridine, 

dihydrouridine, 5-(C
1
-C
6
)-alkyluridine, 5-(C
1
-C
6
)-alkenyluridine, 
5-(C
1
-C
6
)-alkynyluridine, 5-(C
1
-C
6
)-alkylcytidine, 5-(C
1
-C
6
)-alkenylcytidine, 
5-(C
1
-C
6
)-alkynylcytidine, 5-fluorouridine, 
5-fluorocytidine, 5-chlorouridine, 5-chlorocytidine, 5-bromouridine 

or 5-bromocytidine. 
An oligonucleotide as claimed in any of claims 1-6, wherein the 
oligonucleotide has a lipophilic radical, preferably a famesyl, phytyl, 

hexadecyl, cholesteryl, hexamethylenetetraamine, vitamin E or bile 
acid radical, on the 5' and/or the 3' end. 
A process for the preparation of the oligonucleotide as claimed in any 
of claims 1-7, which comprises their chemical synthesis. 
A process for the preparation of a pharmaceutical, which comprises 
mixing at least one oligonucleotide as claimed in any of claims 1-7 with 

a physiologically acceptable excipient and, if appropriate, suitable 
additives and/or auxiliaries. 
The use of the oligonucleotide as claimed in any of claims 1-7 for the 
preparation of a pharmaceutical or diagnostic. 
</CLAIMS>
</TEXT>
</DOC>
